Pfizer Licenses Akcea’s AKCEA-ANGPTL3-LRx

By Michelle Liu

Pharma Deals Review: Vol 2019 Issue 10 (Table of Contents)

Published: 11 Oct-2019

DOI: 10.3833/pdr.v2019.i10.2460     ISSN: 1756-7874

Section: Licensing



Highlighting its commitment to cardiovascular and metabolic diseases, Pfizer has agreed to license AKCEA-ANGPTL3-LRx from Akcea Therapeutics, a majority-owned affiliate of Ionis Pharmaceuticals...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details